<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">	<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">		<head>			<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />			<meta http-equiv="X-UA-Compatible" content="IE=edge" />			<link rel="shortcut icon" href="dailymed/images/favicon.ico" />			<meta name="ROBOTS" content="NOFOLLOW" />				<script type="text/javascript" src="/dailymed/scripts/1.10.2/jquery-1.10.2.min.js"></script>	<script type="text/javascript" src="/dailymed/scripts/jquery-ui/jquery-ui.min.js"></script>	<script type="text/javascript">		var jQuery_1_10_2 = $.noConflict();	</script>	<link rel="stylesheet"   href="dailymed/scripts/jquery-ui/smoothness/jquery-ui.min.css" type="text/css" />	<link rel="stylesheet"   href="dailymed/styles/base-.min.css?v=1.3" type="text/css"  />		<script src="/dailymed/scripts/drop_down-.min.js" type="text/javascript"></script>	<script src="/dailymed/scripts/shared-.min.js" type="text/javascript"></script>	<!--[if IE]>	<link rel="stylesheet" type="text/css" href="dailymed/styles/ie-hacks-.min.css" />	<![endif]-->		<script type="text/javascript" src="/dailymed/scripts/1.3.2/jquery-.min.js"></script> 	<script type="text/javascript" src="/dailymed/scripts/autocomplete/jquery.autocomplete.min.js"></script>	<script type="text/javascript">		$(document).ready(function(){						// check to see if autocomplete plugin has been loaded by looking for existance of "autocomplete" function in jQuery object			if( $.fn.autocomplete ) {  				// THE PLUGIN HAS BEEN LOADED!				//alert(" autocomplete is already loaded! great! ");			}			else {				// reinsert the script tag into the head to load the autocomplete plugin								//alert(" we need to load in autocomplete..." );								$("head").append('<script type="text/javascript" src="/dailymed/scripts/autocomplete/jquery.autocomplete.min.js" />');					}						// actually activate autocomplete			$("#startswith").autocomplete("/dailymed/autocomplete.cfm?key=search",{				width: 275,				selectFirst: false,				cacheLength:1,				max:200,				matchSubset:false,				delay:300,				minChars:3			});		});	 	</script>			<link rel="stylesheet"   href="dailymed/scripts/autocomplete/jquery.autocomplete-.min.css" type="text/css" />	  	<noscript>Your browser does not support JavaScript!</noscript>														<title>KALYDECO (IVACAFTOR) TABLET, FILM COATED [VERTEX PHARMACEUTICALS INCORPORATED]</title>			<link rel="alternate" type="application/rss+xml" href="dailymed/labelrss.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25"			title="RSS Feed for KALYDECO (IVACAFTOR) TABLET, FILM COATED [VERTEX PHARMACEUTICALS INCORPORATED] Label"/>			<link rel="bookmark" href="lookup.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25" title="KALYDECO (IVACAFTOR) TABLET, FILM COATED [VERTEX PHARMACEUTICALS INCORPORATED]" />						<link rel="stylesheet" type="text/css" href="fdastyles/spl-.min.css" />							<link rel="stylesheet" type="text/css" href="styles/layouts/slidingdoors-.min.css" />						<link rel="stylesheet" href="styles/colorbox-.min.css" type="text/css" media="screen" />			<script language="javascript" type="text/javascript" src="scripts/jquery.colorbox-min.js"></script>			<script type="text/javascript" src="scripts/autocomplete/lib/jquery.bgiframe.min.js"></script>			<script type="text/javascript" src="scripts/autocomplete/lib/jquery.dimensions-.min.js"></script>            <script>				$(function() {					jQuery_1_10_2( "#pmi-dialog-confirm" ).dialog({					  resizable: false,					  modal: true,					  autoOpen: false,					  position: {						my: "center",						at: "center",						of: $("body"),						within: $("body")					  }					});									jQuery_1_10_2( "#pmi_link a" ).click( function(event){						event.preventDefault();						var setid = this.toString();						jQuery_1_10_2( "#pmi-dialog-confirm" ).dialog( "option", "buttons", 							[								{									text: "Continue", 									click: function() {										jQuery_1_10_2( this ).dialog( "close" );										window.location.href = setid;									}								},								{									text: "Cancel", 									click: function() {										jQuery_1_10_2( this ).dialog( "close" );									}								}							]						);												jQuery_1_10_2( "#pmi-dialog-confirm" ).dialog( "open" );					});				});			</script>		</head>		<body>							<div id="controls"><ul>    	<li><a class="skipicon1" href="#druglabelcontent" title="Skip to DrugLabel content paragraph">Skip to DrugLabel content</a></li>	<li><a class="skipicon2" href="#dmsections" title="Skip to DrugLabel sections paragraph">Skip to DrugLabel sections</a></li>   </ul></div>  <div id="dailymedbanner">  		<div id="brandimage">        <img src="/dailymed/images/DM_LOGO_HEADER.png" alt="DailyMed Logo Header image" />        </div>        <div id="top">          <h1>Daily            <span>Med</span>          </h1>          <h2>            <span>Current </span>            <span>Medication </span>            <span>Information</span>          </h2>        </div>  </div>						<div id="actions">	<div id="options">		<h2>Options</h2>		<ul id="dmnav">	      		<li>					<a 	title=" Link to DailyMed Home "						href='/dailymed/about.cfm'						id="home">Home</a>				</li>	      		<li>					<a 	title=" Link to E-mail Label Information "						href="dailymed/emailWebLink.cfm"						id="email">E-mail Label Information</a>				</li>				<li><a 	class="rightarrow"						href="#"						title="Links to download options">Downloads</a>					<ul>						<li>							<a	title=" Link opens new window to download all drug labels "								href="dailymed/downloadLabels.cfm">Download All Drug Labels</a>						</li>                        <li>                        	<a	title=" Link opens new window to download all indexing files"                             	href="dailymed/downloadIndexing.cfm">Download All Indexing Files</a>                        </li>                        <li>                        	<a	title=" Link opens new window to download all mapping files"                             	href="dailymed/downloadMappingFiles.cfm">Download All Mapping Files</a>                        </li>                    	<li>                        	<a	title="Link to download FDA SPL Stylesheets"                            	href="http://www.fda.gov/downloads/ForIndustry/DataStandards/StructuredProductLabeling/UCM362812.zip">Download FDA SPL Stylesheets</a>                        </li>												<li>							<a	title=" Link opens new window to download this label (XML) "								href="dailymed/getFile.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25&amp;type=zip&amp;name=KALYDECO">Download this Label(XML)</a>						</li>                        <li>						                        					</ul>				</li>								<li><a 	title="SPL History"						href="dailymed/splshistory.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25"						id="splhistory">SPL History </a>				</li>				<li><a 	title="Link to Print this Label"						href="dailymed/fda/fdaDrugXsl.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25&amp;type=display"						id="printitem"						target="_blank"> Print this Label </a>				</li>                <li>                				                    <a	title="Download PDF of this Label"                             href="dailymed/getFile.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25&amp;type=pdf&amp;name=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25"                            id="downloadpdf"> Download this Label (PDF)</a>                                                               </li>        					      	    <li>						<a	title=" Notify of Updates "						href="dailymed/rsshome.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25"						id="rss">Notify of Updates</a>				</li>	      		<li>					<a	title=" Contact Us "						href="dailymed/contactUs.cfm"						id="contact">Contact Us</a>				</li>                <li>					<a	title=" Help "						href="dailymed/help.cfm"						id="help">Help</a>				</li>                <li>					<a	title=" Web Services "						href="dailymed/help.cfm#webservices"						id="help">Web Services <img src="/dailymed/images/new.gif" alt="New Web Services" /></a>				</li>                <li class="new-option">                	<a	title=" Browse Drug Classes "                    	href="dailymed/browseClasses.cfm"                        id="browse">Browse Drug Classes                    </a>                                    </li>				<li><h2>Additional Resources</h2></li>                <li>                	<a 	class="rightarrow"                		href="#"	                    title="Links to DailyMed presentations and related material">DailyMed Presentations and Related Material</a>                	<ul>                    	<li>                        	<a	href="http://videocast.nih.gov/Summary.asp?File=18134"                            	title="SPL/DailyMed Jamboree Workshop Videocast">SPL/DailyMed Jamboree Workshop Videocast</a>                        </li>                        <li>                        	<a	href="http://www.nlm.nih.gov/mesh/spl_workshop.html"                            	title="SPL/DailyMed Jamboree Workshop Slides">SPL/DailyMed Jamboree Workshop Slides</a>                        </li>                   		<li>                   			<a 	href="http://spl-work-group.wikispaces.com/Bibliography+-+Articles+containing+SPL"                            	title="Articles and Papers about SPL and DailyMed">Articles and Papers about SPL and DailyMed</a>                   		</li>                    </ul>                </li>                <li>                    <a	href="http://www.fda.gov/oc/datacouncil/spl.html"                        title="Link opens in a new window for FDA SPL Resources"                        target="FDA">FDA Structured Product Labeling Resources and Stylesheets                    </a>                </li>				<li>					<a	id="splimagesspec"						href="dailymed/splimagesspec.cfm"						target="SPLIMAGESPEC"						title="SPLIMAGE Specifications">SPLIMAGE Specification Version 3.0.2  </a>				</li>				<li>					<a	id="report"						href="http://www.fda.gov/medwatch/how.htm"						target="FDA"						title="FDA Page to Report Adverse Event">Report Adverse Event</a>				</li>																				    <li><a href="http://www.nlm.nih.gov/search/medlineplus?query=ivacaftor" title="Link opens new window to MedlinePlus Information" target="medlinePlus">MedlinePlus Information</a></li>			    <li><a href="http://www.clinicaltrials.gov/ct/search?submit=Search&amp;term=ivacaftor" title="Link opens new window to Find Clinical Trials" target="clinicalTrials">Find Clinical Trials</a></li>				<li><a href="http://www.drugbank.ca/search?query=ivacaftor" title="Link opens new window to University of Alberta DrugBank" target="drugBank">Biochemical Data Summary</a></li>			    <li><a href="#" class="rightarrow" title="Links to Search PubMed Articles">Search PubMed Articles</a>				  <ul>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ivacaftor[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a></li>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ivacaftor/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a></li>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ivacaftor/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a></li>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ivacaftor/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a></li>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ivacaftor[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a></li>				  </ul>			    </li>				<li>					<a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+lact:@na+ivacaftor" target="toxnet" title="Link opens new window for Presence in Breast Milk">Presence in Breast Milk</a>								</li>                <script> $(function() {			jQuery_1_10_2( "#rximage-dialog-confirm" ).dialog({			  resizable: false,			  modal: true,			  autoOpen: false,			  position: {				my: "center",				at: "center",				of: $("body"),				within: $("body")			  }			});					jQuery_1_10_2( ".rximage-link" ).click( function(event){				event.preventDefault();				jQuery_1_10_2( "#rximage-dialog-confirm" ).dialog( "option", "buttons", 					[						{							text: "Continue", 							click: function() {								jQuery_1_10_2( this ).dialog( "close" );								$( "a.rximage" )[0].click();							}						},						{							text: "Cancel", 							click: function() {								jQuery_1_10_2( this ).dialog( "close" );							}						}					]				);								jQuery_1_10_2( "#rximage-dialog-confirm" ).dialog( "open" );			});						$( ".rximage" ).colorbox({				rel:'rximage',				maxHeight:'100%',				maxWidth:'100%'			});		});</script><div id="rximage-dialog-confirm" title="Disclaimer" style="display:none;">  <p><span class="ui-icon ui-icon-alert" style="float: left;"></span>&nbsp;<strong>Disclaimer:</strong> These images are provided by the National Library of Medicine (NLM) and are not part of the official label.</p> </div>    			            	     </ul>		 		 	<div id="mdswitch">									<a  href="dailymed/drugInfo.cfm?id=129832&amp;dictionary=on"						title="Turn Dictionary Words On">						<img src="/dailymed/images/dictionaryon.jpg" alt="Turn Dictionary Words On"/>					</a>							</div>				</div>							<style type="text/css">		html body {		min-width:1024px;		}        .smallimage {            border: 1px solid ##ACBECE;        }</style>						    	    																																																								    	    	                             		       	                                                               <script>	$(function() {		$( '.splimage' ).colorbox({			rel:'splimage',			maxHeight:'100%',			maxWidth:'100%'		});	});</script>		            </div>			<div id="content">			<div id="searchpane">			<div id="search"><form action="/dailymed/search.cfm" name="searchform"><div class="divtable">    <div class="divtr">            <div class="divtd">Search :</div>            <div class="divtd">            	<label for="startswith" class="invisibletag">Enter a drug Name to search</label>                <input style="width:95%;"                type="text"                 id="startswith"                 name="startswith"                 title="enter a drug name to search"                  onclick="javascript:resetme()" /> &nbsp;                       </div>            <div class="divtd">              	<label for="go" class="invisibletag">Go</label>                <input type="image"                 src="/dailymed/images/goButton.gif"                 alt="Click this button to start your drug name search"                 title="Click this button to start your drug name search"                 id="go"/> &nbsp;            </div>            <div class="divtd80">            	<a href="dailymed/advancedSearch.cfm">Advanced Search</a>            </div>    </div>    <div class="divtr">    		<div class="divtd85">Limits:</div>            <div class="divtd85">                <input  class="searchoptions"  type="radio" name="searchdb" value="drugname" id="name-radio" title="Drug Name" />                <label for="name-radio" class="searchoptions">Drug Name</label>                <input  class="searchoptions"  type="radio" name="searchdb" value="ndc" id="ndc-radio" title="NDC Code" />               	<label for="ndc-radio" class="searchoptions">NDC Code</label>                <input  class="searchoptions"  type="radio" name="searchdb" value="drugclass" id="class-radio" title="Drug Class" />               	<label for="class-radio" class="searchoptions">Drug Class</label>                <input  class="searchoptions"  type="radio" name="searchdb" value="setid" id="setid-radio" title="SETID" />               	<label  for="setid-radio" class="searchoptions">SetId</label>            </div>    </div>    <div class="divtr">            <div class="divtd85">Label Type:</div>            <div class="divtd85" style="float:left;">                <input class="searchoptions" type="radio" name="labeltype" value="human" id="human-radio" title="Human Drugs" />               	<label for="human-radio" class="searchoptions">Human Drugs</label>                <input class="searchoptions" type="radio" name="labeltype" value="animal" id="animal-radio" title="Animal Drugs" />               	<label for="animal-radio" class="searchoptions">Animal Drugs</label>            </div>    </div>          </div></form></div>			</div>					<div id="rxnormlist">		<h3>RxNorm Names</h3>								<ul style="maring:0px; padding:0px;">				<li id="item1" style="padding:1px; margin:1px;">					  						<a 	id="viewrxnorm"							href="rxnormdata.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25"							onclick="rxnormpopup(this.href);return false;"							target="rxnorm" title="Link to Review RxNorm Normal Forms" >							<img src="images/closed.gif"								 alt="Icon attached Review or Hide All RxNorm Normal Forms Link"								 id="img_item1"								 border="0"								 style="clear:none;float:left">Review RxNorm Normal Forms</a>					  			  	</li>			 </ul>				</div>				<!DOCTYPE html PUBLIC "-"><p class="DocumentTitle"><strong>KALYDECO			(ivacaftor) 		 tablet, film coated</strong><br> [Vertex Pharmaceuticals Incorporated] 	</p><br>			<div class="permalink">				<h3><strong>Permanent Link: </strong></h3><span><a href="lookup.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25">http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25 </a><span>			</div>									                                    			<div id="nlmdrugstatus">			<table border="4" width="100%" style="border: 1px solid rgb(142, 1, 10); padding: 0pt; float: right; margin-bottom: 0.75em; margin-top: 0.75em; position: relative; right: 0pt;">			<thead align="left" bgcolor="#F6F6F6" style="color:#8e010a; font-size:1.2em">			<tr>			<th scope="col">				<a class="anchor1" href="http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162063.htm" target="fda"			onclick="fdapopup(this.href);return false;" title="Document Type including Content of Labeling Type">			Category</a></th>			<th scope="col">				<a class="anchor1" href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs/ucm071816.htm" target="fda" onclick="fdapopup(this.href);return false;" title="SPL DEA Schedule">			DEA Schedule</a></th>			<th scope="col">			<a class="anchor1" href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs/ucm071826.htm" target="fda" onclick="fdapopup(this.href);return false;" title="Marketing Category">Marketing Status</a></th>			</tr>			</thead>			<tbody>			<tr>			<td scope="row"><strong>HUMAN PRESCRIPTION DRUG LABEL</strong></td>			<td scope="row"><strong></strong></td>			<td scope="row"><strong>New Drug Application</strong></td>			</tr>			</tbody>			</table>			<div id="disclaimer" >											</div>			</div>			<div id="dmsectionsfieldset"><fieldset><legend>Drug Label Sections</legend><div id="dmsections"><ul><li><a title="Description" href="#nlm34089-3" class="nlmlinktrue">Description</a></li><li><a title="Clinical Pharmacology" href="#nlm34090-1" class="nlmlinktrue">Clinical Pharmacology</a></li><li><a title="Indications &amp; Usage" href="#nlm34067-9" class="nlmlinktrue">Indications &amp; Usage</a></li><li><a title="Contraindications" href="#nlm34070-3" class="nlmlinktrue">Contraindications</a></li><li><a title="Warnings" href="#nlm43685-7" class="nlmlinktrue">Warnings</a></li><li><a title="Precautions" href="#nlm43685-7" class="nlmlinktrue">Precautions</a></li><li><a title="Adverse Reactions" href="#nlm34084-4" class="nlmlinktrue">Adverse Reactions</a></li><li><a title="Overdosage" href="#nlm34088-5" class="nlmlinktrue">Overdosage</a></li><li><a title="Dosage &amp; Administration" href="#nlm34068-7" class="nlmlinktrue">Dosage &amp; Administration</a></li><li><a title="How Supplied" href="#nlm34069-5" class="nlmlinktrue">How Supplied</a></li><li><a title="Patient Counseling Information" href="#nlm34076-0" class="nlmlinktrue">Patient Counseling Information</a></li><li><a title="Supplemental Patient Material" href="#nlm38056-8" class="nlmlinkfalse">Supplemental Patient Material</a></li><li><a title="Boxed Warning" href="#nlm34066-1" class="nlmlinkfalse">Boxed Warning</a></li><li><a title="Patient Package Insert" href="#nlm42230-3" class="nlmlinktrue">Patient Package Insert</a></li><li><a title="Highlights" href="#nlmhighlights" class="nlmlinktrue">Highlights</a></li><li><a title="Full Table of Contents" href="javascript:nlmftoc('nlmftoc');" class="nlmlinktrue">Full Table of Contents</a></li><li><a href="#" class="nlmlinkfalse">Medication Guide</a></li></ul></div></fieldset></div>			<div class="spl">				<a name="druglabelcontent"></a><div id="nlmhighlightsmarker"><div class="Highlights" id="Highlights"><table border="0" style="table-layout:fixed" width="100%" cellpadding="5" cellspacing="5"><tr><td valign="top" align="left" width="50%"><div><a name="nlmhighlights"><h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1></a><div class="HighlightsDisclaimer">These highlights do not include all the information needed to use KALYDECO safely and effectively.  See full prescribing information for KALYDECO.<br><br>KALYDECO<span class="Sup">&reg;</span> (ivacaftor) Tablets, for oral use<br>Initial U.S. Approval: 2012</div><div class="HighlightSection"><h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1><div><table class="Noautorules" width="75%"><col align="left" valign="top" width="80%"><col align="left" valign="top" width="20%"><tbody class="Headless"><tr><td align="left"><ul><li>Indications and Usage (<a href="#S1">1</a>)</li></ul></td><td align="left">02/2014</td></tr></tbody></table></div></div><div></div><div class="HighlightSection"><h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1><div><p class="Highlighta">KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the <span class="Italics">CFTR</span> gene: <span class="Italics">G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, </span>or<span class="Italics"> S549R</span>. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a <span class="Italics">CFTR</span> mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. (<a href="#S1">1</a>) </p><p class="Highlighta"><span class="Italics">Limitations of Use:</span> </p><ul class="Disc"><li>Not effective in patients with CF who are homozygous for the <span class="Italics">F508del</span> mutation in the <span class="Italics">CFTR</span> gene. (<a href="#S1">1</a>, <a href="#S14">14</a>)</li></ul></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1><div><ul class="Disc"><li> Adults and pediatric patients age 6 years and older: one 150 mg tablet taken orally every 12 hours with fat-containing food. (<a href="#S2.1">2.1</a>, <a href="#S12.3">12.3</a>)</li><li> Reduce dose in patients with moderate and severe hepatic impairment. (<a href="#S2.2">2.2</a>, <a href="#S8.6">8.6</a>, <a href="#S12.3">12.3</a>)</li><li> Reduce dose when co-administered with drugs that are moderate or strong CYP3A inhibitors. (<a href="#S2.3">2.3</a>, <a href="#S7.1">7.1</a>, <a href="#S12.3">12.3</a>)</li></ul></div><div></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1><div><ul class="Disc"><li>Tablets: 150 mg (<a href="#S3">3</a>)</li></ul></div></div><div class="HighlightSection"><h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1><div><ul class="Disc"><li>None (<a href="#S4">4</a>)</li></ul></div></div><div class="HighlightSection"><h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1><div><ul class="Disc"><li> Elevated transaminases (ALT or AST): Transaminases (ALT and AST) should be assessed prior to initiating KALYDECO, every 3 months during the first year of treatment, and annually thereafter. Patients who develop increased transaminase levels should be closely monitored until the abnormalities resolve. Dosing should be interrupted in patients with ALT or AST of greater than 5 times the upper limit of normal (ULN). Following resolution of transaminase elevations, consider the benefits and risks of resuming KALYDECO dosing. (<a href="#S5.1">5.1</a>, <a href="#S6">6</a>)</li><li> Use with CYP3A inducers: Concomitant use with strong CYP3A inducers (e.g., rifampin, St. John's Wort) substantially decreases exposure of ivacaftor, which may diminish effectiveness. Therefore, co-administration is not recommended. (<a href="#S5.2">5.2</a>, <a href="#S7.2">7.2</a>, <a href="#S12.3">12.3</a>)</li></ul></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1><div><p class="Highlighta">The most common adverse drug reactions to KALYDECO (occurring in &ge;8% of patients with CF who have a <span class="Italics">G551D</span> mutation in the <span class="Italics">CFTR</span> gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness. (<a href="#S6.1">6.1</a>)<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Vertex Pharmaceuticals Incorporated at 1-877-752-5933 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p></div><div><div></div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1><div><p class="Highlighta">CYP3A inhibitors: Reduce KALYDECO dose to 150 mg twice a week when co-administered with strong CYP3A inhibitors (e.g., ketoconazole). Reduce KALYDECO dose to 150 mg once daily when co-administered with moderate CYP3A inhibitors (e.g., fluconazole). Avoid food containing grapefruit or Seville oranges. (<a href="#S7.1">7.1</a>, <a href="#S12.3">12.3</a>) </p></div><div></div><div></div><div></div></div><div><div><div></div></div><div></div><div></div><div></div><div></div><div></div></div><div></div><div></div><div><div></div><div><div></div><div></div></div><div><div></div><div></div><div></div><div></div><div><div></div><div></div><div></div><div></div><div></div><div></div></div></div></div><div><div></div><div></div></div><div><div><div></div><div></div></div><div></div><div></div></div><div><div></div></div><div><div></div><div></div><div></div><div></div></div><div></div><div></div><div></div><div></div><p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p><p class="HighlightsRevision">Revised: 6/2014</p></div></td></tr></table></div></div><div id="nlmftoc"><span id="backtodmsections"><a title=" Back to Highlights and Tabs " href="javascript:nlmftoc('backtodmsections');">Back to Highlights and Tabs</a></span><div class="Index" id="Index"><table style="table-layout:fixed" width="100%" cellpadding="5" cellspacing="5"><tr><td valign="top" align="left" width="50%"><div><h1 class="Colspan"><a style="text-decoration:none;" name="dmsections">FULL PRESCRIBING INFORMATION: CONTENTS</a><a name="footnote-reference-content" href="#footnote-content">*</a></h1><h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1><h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1><h2><a href="#section-2.1" class="toc">2.1	Dosing Information in Adults and Children Ages 6 Years and Older</a></h2><h2><a href="#section-2.2" class="toc">2.2	Dosage Adjustment for Patients with Hepatic Impairment</a></h2><h2><a href="#section-2.3" class="toc">2.3	Dosage Adjustment for Patients Taking Drugs that are CYP3A Inhibitors</a></h2><h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1><h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1><h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1><h2><a href="#section-5.1" class="toc">5.1	Transaminase (ALT or AST) Elevations</a></h2><h2><a href="#section-5.2" class="toc">5.2	Concomitant Use with CYP3A Inducers</a></h2><h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1><h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2><h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1><h2><a href="#section-7.1" class="toc">7.1	Inhibitors of CYP3A</a></h2><h2><a href="#section-7.2" class="toc">7.2	Inducers of CYP3A</a></h2><h2><a href="#section-7.3" class="toc">7.3	CYP3A and/or P-gp Substrates</a></h2><h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1><h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2><h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2><h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2><h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2><h2><a href="#section-8.5" class="toc">8.6	Hepatic Impairment</a></h2><h2><a href="#section-8.6" class="toc">8.7	Renal Impairment</a></h2><h2><a href="#section-8.7" class="toc">8.8	Patients with CF who are Homozygous for the <span class="Italics">F508del</span> Mutation in the <span class="Italics">CFTR</span> Gene</a></h2><h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1><h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1><h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1><h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2><h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2><h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2><h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1><h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2><h2><a href="#section-12.2" class="toc">13.2	Animal Toxicology and/or Pharmacology</a></h2><h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1><h2><a href="#section-13.1" class="toc">14.1	Trials in Patients with CF who have a <span class="Italics">G551D</span> Mutation in the <span class="Italics">CFTR</span> Gene</a></h2><h2><a href="#section-13.2" class="toc">14.2         Trial in Patients with a <span class="Italics">G1244E, G1349D, G178R, G551S, G970R, S1251N, S1255P, S549N,</span> or<span class="Italics"> S549R</span> Mutation in the <span class="Italics">CFTR</span> Gene</a></h2><h2><a href="#section-13.3" class="toc">14.3	Trial in Patients Homozygous for the <span class="Italics">F508del</span> Mutation in the <span class="Italics">CFTR</span> Gene</a></h2><h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1><h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1><h2><a href="#section-15.1" class="toc">17.1 	Transaminase (ALT or AST) Elevations and Monitoring</a></h2><h2><a href="#section-15.2" class="toc">17.2 	Drug Interactions with CYP3A Inducers and Inhibitors</a></h2><h2><a href="#section-15.3" class="toc">17.3 	Use in Patients with Hepatic Impairment</a></h2><h2><a href="#section-15.4" class="toc">17.4 	Take with Fat-Containing Food</a></h2><dl class="Footnote"><dt><a name="footnote-content" href="#footnote-reference-content">*</a></dt><dd>Sections or subsections omitted from the full prescribing information are not listed.</dd></dl></div></td></tr></table></div></div><div class="Contents"><h1>FULL PRESCRIBING INFORMATION</h1><div class="Section"><a name="nlm48780-1"></a><a name="DLDE"></a><a name="section-1"></a><p></p></div><div class="Section"><a name="nlm34067-9"></a><a name="S1"></a><a name="section-1"></a><p></p><h1>1 INDICATIONS AND USAGE</h1><p class="First" style="border-left:1px solid;"><span class="XmChange">KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the <span class="Italics">CFTR</span> gene: <span class="Italics">G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, </span>or<span class="Italics"> S549R</span>. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a <span class="Italics">CFTR</span> mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.</span></p><div class="Section"><a name="nlm42229-5"></a><a name="section-1.1"></a><p></p><p class="First"><span class="Italics">Limitations of Use</span></p><p>KALYDECO is not effective in patients with CF who are homozygous for the <span class="Italics">F508del</span> mutation in the <span class="Italics">CFTR </span>gene.</p></div></div><div class="Section"><a name="nlm34068-7"></a><a name="S2"></a><a name="section-2"></a><p></p><h1>2 DOSAGE AND ADMINISTRATION</h1><div class="Section"><a name="nlm42229-5"></a><a name="S2.1"></a><a name="section-2.1"></a><p></p><h2>2.1	Dosing Information in Adults and Children Ages 6 Years and Older</h2><p class="First">The recommended dose of KALYDECO for both adults and pediatric patients age 6 years and older is one 150 mg tablet taken orally every 12 hours (300 mg total daily dose) with fat-containing food. Examples of appropriate fat-containing foods include eggs, butter, peanut butter, cheese pizza, etc. [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span> and<span class="Italics"><a href="#S17.4"> Patient Counseling Information (17.4)</a></span>].</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S2.2"></a><a name="section-2.2"></a><p></p><h2>2.2	Dosage Adjustment for Patients with Hepatic Impairment</h2><p class="First">The dose of KALYDECO should be reduced to 150 mg once daily for patients with moderate hepatic impairment (Child-Pugh Class B). KALYDECO should be used with caution in patients with severe hepatic impairment (Child-Pugh Class C) at a dose of 150 mg once daily or less frequently [<span class="Italics">see <a href="#S8.6">Use in Specific Populations (8.6)</a>, <a href="#S12.3">Clinical Pharmacology (12.3)</a>,</span> and <span class="Italics"><a href="#S17.3">Patient Counseling Information (17.3)</a></span>].</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S2.3"></a><a name="section-2.3"></a><p></p><h2>2.3	Dosage Adjustment for Patients Taking Drugs that are CYP3A Inhibitors</h2><p class="First">When KALYDECO is being co-administered with strong CYP3A inhibitors (e.g., ketoconazole), the dose should be reduced to 150 mg twice a week. The dose of KALYDECO should be reduced to 150 mg once daily when co-administered with moderate CYP3A inhibitors (e.g., fluconazole). Food containing grapefruit or Seville oranges should be avoided [<span class="Italics">see <a href="#S7.1">Drug Interactions (7.1)</a>, <a href="#S12.3">Clinical Pharmacology (12.3)</a>,</span> and<span class="Italics"><a href="#S17.2"> Patient Counseling Information (17.2)</a></span>].</p></div></div><div class="Section"><a name="nlm43678-2"></a><a name="S3"></a><a name="section-3"></a><p></p><h1>3 DOSAGE FORMS AND STRENGTHS</h1><p class="First">150 mg tablets.</p></div><div class="Section"><a name="nlm34070-3"></a><a name="S4"></a><a name="section-4"></a><p></p><h1>4 CONTRAINDICATIONS</h1><p class="First">None</p></div><div class="Section"><a name="nlm43685-7"></a><a name="S5"></a><a name="section-5"></a><p></p><h1>5 WARNINGS AND PRECAUTIONS</h1><div class="Section"><a name="nlm42229-5"></a><a name="S5.1"></a><a name="section-5.1"></a><p></p><h2>5.1	Transaminase (ALT or AST) Elevations</h2><p class="First">Elevated transaminases have been reported in patients with CF receiving KALYDECO. It is recommended that ALT and AST be assessed prior to initiating KALYDECO, every 3 months during the first year of treatment, and annually thereafter. Patients who develop increased transaminase levels should be closely monitored until the abnormalities resolve. Dosing should be interrupted in patients with ALT or AST of greater than 5 times the upper limit of normal (ULN). Following resolution of transaminase elevations, consider the benefits and risks of resuming KALYDECO dosing [<span class="Italics">see <a href="#S6">Adverse Reactions (6)</a></span>].</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S5.2"></a><a name="section-5.2"></a><p></p><h2>5.2	Concomitant Use with CYP3A Inducers</h2><p class="First">Use of KALYDECO with strong CYP3A inducers, such as rifampin, substantially decreases the exposure of ivacaftor, which may reduce the therapeutic effectiveness of KALYDECO. Therefore, co-administration of KALYDECO with strong CYP3A inducers (e.g., rifampin, St. John's Wort) is not recommended [<span class="Italics">see <a href="#S7.2">Drug Interactions (7.2)</a></span> and<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>].</p></div></div><div class="Section"><a name="nlm34084-4"></a><a name="S6"></a><a name="section-6"></a><p></p><h1>6 ADVERSE REACTIONS</h1><p class="First">The following adverse reaction is discussed in greater detail in other sections of the label:</p><ul><li>Transaminase Elevations [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>]</li></ul><div class="Section"><a name="nlm42229-5"></a><a name="S6.1"></a><a name="section-6.1"></a><p></p><h2>6.1 Clinical Trials Experience</h2><p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p><p>The overall safety profile of KALYDECO is based on pooled data from three placebo-controlled clinical trials conducted in 353 patients with CF who had a <span class="Italics">G551D</span> mutation in the <span class="Italics">CFTR</span> gene (Trials 1 and 2) or were homozygous for the <span class="Italics">F508del </span>mutation (Trial 3). In addition, an 8-week crossover design trial (Trial 4) involving 39 patients with a <span class="Italics">G1244E, G1349D, G178R, G551S, G970R, S1251N, S1255P, S549N, </span>or<span class="Italics"> S549R</span> mutation in the <span class="Italics">CFTR</span> gene was conducted. Patients treated with KALYDECO in these trials were between the ages of 6 and 57 years.</p><p>Of the 353 patients included in the pooled analyses of patients with CF who had either a <span class="Italics">G551D</span> mutation or were homozygous for the <span class="Italics">F508del</span> mutation in the <span class="Italics">CFTR</span> gene, 50% of patients were female and 97% were Caucasian; 221 received KALYDECO and 132 received placebo from 16 to 48 weeks.</p><p>The proportion of patients who prematurely discontinued study drug due to adverse reactions was 2% for KALYDECO-treated patients and 5% for placebo-treated patients. Serious adverse reactions, whether considered drug-related or not by the investigators, that occurred more frequently in KALYDECO-treated patients included abdominal pain, increased hepatic enzymes, and hypoglycemia.</p><p>The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).</p><p>The incidence of adverse reactions below is based upon two double-blind, placebo-controlled, 48-week clinical trials (Trials 1 and 2) in a total of 213 patients with CF ages 6 to 53 who have a <span class="Italics">G551D</span> mutation in the <span class="Italics">CFTR</span> gene and who were treated with KALYDECO 150 mg orally or placebo twice daily. Table 1 shows adverse reactions occurring in &ge;8% of KALYDECO-treated patients with CF who have a <span class="Italics">G551D</span> mutation in the <span class="Italics">CFTR</span> gene that also occurred at a higher rate than in the placebo-treated patients in the two double-blind, placebo-controlled trials.</p><a name="table1"></a><table width="75%"><caption><span>Table 1: Incidence of Adverse Drug Reactions in &ge;8% of KALYDECO-Treated Patients with a G551D Mutation in the CFTR Gene and Greater than Placebo in 2 Placebo-Controlled Phase 3 Clinical Trials of 48 Weeks Duration</span></caption><col align="left" valign="bottom" width="40%"><col align="center" valign="bottom" width="30%"><col align="center" valign="bottom" width="30%"><thead><tr class="First"><th align="left"></th><th class="Botrule" align="center" colspan="2">Incidence: Pooled 48-week Trials</th></tr><tr class="Botrule Last"><th align="left">Adverse Reaction<br>(Preferred Term)</th><th align="center">KALYDECO<br>N=109<br>n (%)</th><th align="center">Placebo<br>N=104<br>n (%)</th></tr></thead><tbody><tr class="First"><td align="left">Headache</td><td align="center">26 (24)</td><td align="center">17 (16)</td></tr><tr><td align="left">Oropharyngeal pain</td><td align="center">24 (22)</td><td align="center">19 (18)</td></tr><tr><td align="left">Upper respiratory tract infection</td><td align="center">24 (22)</td><td align="center">14 (14)</td></tr><tr><td align="left">Nasal congestion</td><td align="center">22 (20)</td><td align="center">16 (15)</td></tr><tr><td align="left">Abdominal pain</td><td align="center">17 (16)</td><td align="center">13 (13)</td></tr><tr><td align="left">Nasopharyngitis</td><td align="center">16 (15)</td><td align="center">12 (12)</td></tr><tr><td align="left">Diarrhea</td><td align="center">14 (13)</td><td align="center">10 (10)</td></tr><tr><td align="left">Rash</td><td align="center">14 (13)</td><td align="center">7 (7)</td></tr><tr><td align="left">Nausea</td><td align="center">13 (12)</td><td align="center">11 (11)</td></tr><tr class="Botrule Last"><td align="left">Dizziness</td><td align="center">10 (9)</td><td align="center">1 (1)</td></tr></tbody></table><p>Adverse reactions in the 48-week clinical trials that occurred in the KALYDECO group at a frequency of 4 to 7% where rates exceeded that in the placebo group include:</p><p><span class="Bold">Infections and infestations:</span> rhinitis</p><p><span class="Bold">Investigations:</span> aspartate aminotransferase increased, bacteria in sputum, blood glucose increased, hepatic enzyme increased</p><p><span class="Bold">Musculoskeletal and connective tissue disorders:</span> arthralgia, musculoskeletal chest pain, myalgia</p><p><span class="Bold">Nervous system disorders:</span> sinus headache</p><p><span class="Bold">Respiratory, thoracic and mediastinal disorders:</span>  pharyngeal erythema, pleuritic pain, sinus congestion, wheezing</p><p><span class="Bold">Skin and subcutaneous tissue disorders:</span> acne</p><div class="Section"><a name="nlm42229-5"></a><a name="section-6.1.1"></a><p></p><p class="First"><span class="Bold">Laboratory Abnormalities</span></p><p><span class="Italics">Transaminase Elevations:</span>  During 48-week placebo-controlled clinical studies, the incidence of maximum transaminase (ALT or AST) &gt;8, &gt;5 or &gt;3 &times; ULN was 2%, 3% and 6% in KALYDECO-treated patients and 2%, 2% and 8% in placebo-treated patients, respectively. Two patients (2%) on placebo and 1 patient (0.5 %) on KALYDECO permanently discontinued treatment for elevated transaminases, all &gt;8 &times; ULN. Two patients treated with KALYDECO were reported to have serious adverse reactions of elevated liver transaminases compared to none on placebo [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</p><p>The safety profile for the 39 patients with CF with a <span class="Italics">G1244E, G1349D, G178R, G551S, G970R, S1251N, S1255P, S549N, </span>or<span class="Italics"> S549R </span>mutation enrolled in the 8-week crossover trial (Trial 4) was similar to that observed in the 48-week placebo-controlled trials (Trials 1 and 2).</p></div></div></div><div class="Section"><a name="nlm34073-7"></a><a name="S7"></a><a name="section-7"></a><p></p><h1>7 DRUG INTERACTIONS</h1><p class="First"><span class="Bold Italics">Potential for other drugs to affect ivacaftor</span></p><div class="Section"><a name="nlm42229-5"></a><a name="S7.1"></a><a name="section-7.1"></a><p></p><h2>7.1	Inhibitors of CYP3A</h2><p class="First">Ivacaftor is a sensitive CYP3A substrate. Co-administration with ketoconazole, a strong CYP3A inhibitor, significantly increased ivacaftor exposure [measured as area under the curve (AUC)] by 8.5-fold. Based on simulations of these results, a reduction of the KALYDECO dose to 150 mg twice a week is recommended for co-administration with strong CYP3A inhibitors, such as ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, and clarithromycin.</p><p>Co-administration with fluconazole, a moderate inhibitor of CYP3A, increased ivacaftor exposure by 3-fold. Therefore, a reduction of the KALYDECO dose to 150 mg once daily is recommended for patients taking concomitant moderate CYP3A inhibitors, such as fluconazole and erythromycin.</p><p>Co-administration of KALYDECO with grapefruit juice, which contains one or more components that moderately inhibit CYP3A, may increase exposure of ivacaftor. Therefore, food containing grapefruit or Seville oranges should be avoided during treatment with KALYDECO [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S7.2"></a><a name="section-7.2"></a><p></p><h2>7.2	Inducers of CYP3A</h2><p class="First">Co-administration with rifampin, a strong CYP3A inducer, significantly decreased ivacaftor exposure (AUC) by approximately 9-fold. Therefore, co-administration with strong CYP3A inducers, such as rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, and St. John's Wort is not recommended [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2)</a></span> and <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p><p><span class="Bold Italics">Potential for ivacaftor to affect other drugs</span></p></div><div class="Section"><a name="nlm42229-5"></a><a name="S7.3"></a><a name="section-7.3"></a><p></p><h2>7.3	CYP3A and/or P-gp Substrates</h2><p class="First">Ivacaftor and its M1 metabolite have the potential to inhibit CYP3A and P-gp. Co-administration with midazolam, a sensitive CYP3A substrate, increased midazolam exposure 1.5-fold, consistent with weak inhibition of CYP3A by ivacaftor. Co-administration with digoxin, a sensitive P-gp substrate, increased digoxin exposure by 1.3-fold, consistent with weak inhibition of P-gp by ivacaftor. Administration of KALYDECO may increase systemic exposure of drugs that are substrates of CYP3A and/or P-gp, which may increase or prolong their therapeutic effect and adverse events. Therefore, caution and appropriate monitoring are recommended when co-administering KALYDECO with CYP3A and/or P-gp substrates, such as digoxin, cyclosporine, and tacrolimus [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p></div></div><div class="Section"><a name="nlm43684-0"></a><a name="S8"></a><a name="section-8"></a><p></p><h1>8 USE IN SPECIFIC POPULATIONS</h1><div class="Section"><a name="nlm42228-7"></a><a name="S8.1"></a><a name="section-8.1"></a><p></p><h2>8.1 Pregnancy</h2><div class="Section"><a name="nlm34077-8"></a><a name="section-8.1.1"></a><p></p><p class="First"><span class="Bold">Teratogenic effects: Pregnancy Category B.</span> There are no adequate and well-controlled studies of KALYDECO in pregnant women. Ivacaftor was not teratogenic in rats at approximately 6 times the maximum recommended human dose (MRHD) (based on summed AUCs for ivacaftor and its metabolites at a maternal dose of 200 mg/kg/day). Ivacaftor was not teratogenic in rabbits at approximately 12 times the MRHD (on an ivacaftor AUC basis at a maternal dose of 100 mg/kg/day, respectively). Placental transfer of ivacaftor was observed in pregnant rats and rabbits. Because animal reproduction studies are not always predictive of human response, KALYDECO should be used during pregnancy only if clearly needed.</p></div></div><div class="Section"><a name="nlm34080-2"></a><a name="S8.3"></a><a name="section-8.2"></a><p></p><h2>8.3 Nursing Mothers</h2><p class="First">Ivacaftor is excreted into the milk of lactating female rats. Excretion of ivacaftor into human milk is probable. There are no human studies that have investigated the effects of ivacaftor on breast-fed infants. Caution should be exercised when KALYDECO is administered to a nursing woman.</p></div><div class="Section"><a name="nlm34081-0"></a><a name="S8.4"></a><a name="section-8.3"></a><p></p><h2>8.4 Pediatric Use</h2><p class="First">The safety and efficacy of KALYDECO in patients 6 to 17 years of age with CF who have a <span class="Italics">G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, </span>or<span class="Italics"> S549R </span>mutation in the <span class="Italics">CFTR</span> gene has been demonstrated [<span class="Italics">see <a href="#S6">Adverse Reactions (6)</a></span> and <span class="Italics"><a href="#S14">Clinical Studies (14)</a></span>].</p><p>The safety and efficacy of KALYDECO in patients with CF younger than age 6 years have not been established.</p></div><div class="Section"><a name="nlm34082-8"></a><a name="S8.5"></a><a name="section-8.4"></a><p></p><h2>8.5 Geriatric Use</h2><p class="First">CF is largely a disease of children and young adults. Clinical trials of KALYDECO did not include sufficient numbers of patients 65 years of age and over to determine whether they respond differently from younger patients.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S8.6"></a><a name="section-8.5"></a><p></p><h2>8.6	Hepatic Impairment</h2><p class="First">No dose adjustment is necessary for patients with mild hepatic impairment (Child-Pugh Class A). A reduced dose of 150 mg once daily is recommended in patients with moderate hepatic impairment (Child-Pugh Class B). Studies have not been conducted in patients with severe hepatic impairment (Child-Pugh Class C) but exposure is expected to be higher than in patients with moderate hepatic impairment. Therefore, use with caution at a dose of 150 mg once daily or less frequently in patients with severe hepatic impairment after weighing the risks and benefits of treatment [<span class="Italics">see <a href="#S12.3">Pharmacokinetics (12.3)</a></span>].</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S8.7"></a><a name="section-8.6"></a><p></p><h2>8.7	Renal Impairment</h2><p class="First">KALYDECO has not been studied in patients with mild, moderate, or severe renal impairment or in patients with end-stage renal disease. No dose adjustment is necessary for patients with mild to moderate renal impairment; however, caution is recommended while using KALYDECO in patients with severe renal impairment (creatinine clearance less than or equal to 30 mL/min) or end-stage renal disease.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S8.8"></a><a name="section-8.7"></a><p></p><h2>8.8	Patients with CF who are Homozygous for the <span class="Italics">F508del</span> Mutation in the <span class="Italics">CFTR</span> Gene</h2><p class="First">Efficacy results from a double-blind, placebo-controlled trial in patients with CF who are homozygous for the <span class="Italics">F508del</span> mutation in the <span class="Italics">CFTR</span> gene showed no statistically significant difference in forced expiratory volume exhaled in one second (FEV<span class="Sub">1</span>) over 16 weeks of KALYDECO treatment compared to placebo [<span class="Italics">see <a href="#S14.3">Clinical Studies (14.3)</a></span>]. Therefore, KALYDECO should not be used in patients homozygous for the <span class="Italics">F508del </span>mutation in the <span class="Italics">CFTR</span> gene.</p></div></div><div class="Section"><a name="nlm34088-5"></a><a name="S10"></a><a name="section-9"></a><p></p><h1>10 OVERDOSAGE</h1><p class="First">There have been no reports of overdose with KALYDECO.</p><p>The highest single dose used in a clinical study was 800 mg in a solution formulation without any treatment-related adverse events.</p><p>The highest repeated dose was 450 mg (in a tablet formulation) every 12 hours for 4.5 days (9 doses) in a trial evaluating the effect of KALYDECO on ECGs in healthy subjects. Adverse events reported at a higher incidence compared to placebo included dizziness and diarrhea.</p><p>No specific antidote is available for overdose with KALYDECO. Treatment of overdose with KALYDECO consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient.</p></div><div class="Section"><a name="nlm34089-3"></a><a name="S11"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">The active ingredient in KALYDECO tablets is ivacaftor, which has the following chemical name: <span class="Italics">N</span>-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide. Its molecular formula is C<span class="Sub">24</span>H<span class="Sub">28</span>N<span class="Sub">2</span>O<span class="Sub">3 </span>and its molecular weight is 392.49. Ivacaftor has the following structural formula:</p><div class="Figure"><img src="image.cfm?id=129832&type=img&name=kalydeco%2D01.jpg" alt="Chemical Structure"></div><p>Ivacaftor is a white to off-white powder that is practically insoluble in water (&lt;0.05 microgram/mL).</p><p>KALYDECO is available as a light blue capsule-shaped, film-coated tablet for oral administration containing 150 mg of ivacaftor. Each tablet contains the inactive ingredients colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The tablet film coat contains carnauba wax, FD&amp;C Blue #2, PEG 3350, polyvinyl alcohol, talc, and titanium dioxide. The printing ink contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac.</p></div><div class="Section"><a name="nlm34090-1"></a><a name="S12"></a><a name="section-11"></a><p></p><h1>12 CLINICAL PHARMACOLOGY</h1><div class="Section"><a name="nlm43679-0"></a><a name="S12.1"></a><a name="section-11.1"></a><p></p><h2>12.1	Mechanism of Action</h2><p class="First">Ivacaftor is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Ivacaftor facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein.</p><p>In vitro, ivacaftor increased CFTR-mediated transepithelial current (I<span class="Sub">T</span>) in rodent cells expressing the G551D-CFTR protein following addition of a cyclic adenosine monophosphate (cAMP) agonist with an EC<span class="Sub">50</span> of 100 &plusmn; 47 nM; however, ivacaftor did not increase I<span class="Sub">T</span> in the absence of cAMP agonist. Ivacaftor also increased I<span class="Sub">T</span> in human bronchial epithelial cells expressing G551D-CFTR protein following addition of a cAMP agonist by 10-fold with an EC<span class="Sub">50</span> of 236 &plusmn; 200 nM. Ivacaftor increased the open probability of G551D-CFTR protein in single channel patch clamp experiments using membrane patches from rodent cells expressing G551D-CFTR protein by 6-fold versus untreated cells after addition of PKA and ATP. In addition to G551D-CFTR, ivacaftor increased the channel-open probability of other mutant CFTR forms expressed in rodent cells, resulting in enhanced CFTR-mediated I<span class="Sub">T</span>. These mutant CFTR forms included G178R-, S549N-, S549R-, G551S-, G970R-, G1244E-, S1251N-, S1255P-, and G1349D-CFTR. In vitro responses do not necessarily correspond to in vivo pharmacodynamic response or clinical benefit.</p></div><div class="Section"><a name="nlm43681-6"></a><a name="S12.2"></a><a name="section-11.2"></a><p></p><h2>12.2 Pharmacodynamics</h2><div class="Section"><a name="nlm42229-5"></a><a name="section-11.2.1"></a><p></p><p class="First"><span class="Bold Italics">Sweat Chloride Evaluation</span></p><p>Changes in sweat chloride response to KALYDECO were evaluated in four clinical trials. In two randomized, double-blind, placebo-controlled clinical trials in patients with a <span class="Italics">G551D</span> mutation in the <span class="Italics">CFTR</span> gene, one in patients 12 and older (Trial 1) and the other in patients 6-11 years of age (Trial 2), the treatment difference (between KALYDECO and placebo) in mean change in sweat chloride from baseline through Week 24 was -48 mmol/L (95% CI -51, -45) and -54 mmol/L (95% CI -62, -47), respectively. These changes persisted through 48 weeks. In a 16-week randomized, double-blind, placebo-controlled, parallel-group clinical trial in patients with CF age 12-years and older who were homozygous for the <span class="Italics">F508del</span> mutation in the <span class="Italics">CFTR</span> gene (Trial 3), the treatment difference in mean change in sweat chloride from baseline through 8 weeks of treatment was -3 mmol/L (95% CI -6, -0.2). In a two-part, randomized, double-blind, placebo-controlled, crossover clinical trial in patients with CF who had a <span class="Italics">G1244E, G1349D, G178R, G551S, G970R, S1251N, S1255P, S549N, </span>or<span class="Italics"> S549R </span>mutation in the <span class="Italics">CFTR</span> gene (Trial 4), the treatment difference in mean change in sweat chloride from baseline through 8 weeks of treatment was -49 mmol/L (95% CI -57, -41). In Trial 4, mean changes in sweat chloride for the mutations for which KALYDECO is indicated ranged from -51 to -78, whereas the range for individual subjects with the <span class="Italics">G970R </span>mutations was -1 to -11 mmol/L.</p><p>There was no direct correlation between decrease in sweat chloride levels and improvement in lung function (FEV<span class="Sub">1</span>).</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-11.2.2"></a><p></p><p class="First"><span class="Bold Italics">ECG Evaluation</span></p><p>The effect of multiple doses of ivacaftor 150 mg and 450 mg twice daily on QTc interval was evaluated in a randomized, placebo- and active-controlled (moxifloxacin 400 mg) four-period crossover thorough QT study in 72 healthy subjects. In a study with demonstrated ability to detect small effects, the upper bound of the one-sided 95% confidence interval for the largest placebo adjusted, baseline-corrected QTc based on Fridericia's correction method (QTcF) was below 10 ms, the threshold for regulatory concern.</p></div></div><div class="Section"><a name="nlm43682-4"></a><a name="S12.3"></a><a name="section-11.3"></a><p></p><h2>12.3 Pharmacokinetics</h2><p class="First">The pharmacokinetics of ivacaftor is similar between healthy adult volunteers and patients with CF.</p><p>After oral administration of a single 150 mg dose to healthy volunteers in a fed state, peak plasma concentrations (T<span class="Sub">max</span>) occurred at approximately 4 hours, and the mean (&plusmn;SD) for AUC and C<span class="Sub">max</span> were 10600 (5260) ng*hr/mL and 768 (233) ng/mL, respectively.</p><p>After every 12-hour dosing, steady-state plasma concentrations of ivacaftor were reached by days 3 to 5, with an accumulation ratio ranging from 2.2 to 2.9.</p><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.1"></a><p></p><p class="First"><span class="Italics">Absorption</span></p><p>The exposure of ivacaftor increased approximately 2- to 4-fold when given with food containing fat. Therefore, KALYDECO should be administered with fat-containing food. Examples of fat-containing foods include eggs, butter, peanut butter, and cheese pizza. The median (range) T<span class="Sub">max</span> is approximately 4.0 (3.0; 6.0) hours in the fed state.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.2"></a><p></p><p class="First"><span class="Italics">Distribution</span></p><p>Ivacaftor is approximately 99% bound to plasma proteins, primarily to alpha 1-acid glycoprotein and albumin. Ivacaftor does not bind to human red blood cells.</p><p>The mean apparent volume of distribution (Vz/F) of ivacaftor after a single dose of 275 mg of KALYDECO in the fed state was similar for healthy subjects and patients with CF. After oral administration of 150 mg every 12 hours for 7 days to healthy volunteers in a fed state, the mean (&plusmn;SD) for apparent volume of distribution was 353 (122) L.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.3"></a><p></p><p class="First"><span class="Italics">Metabolism</span></p><p>Ivacaftor is extensively metabolized in humans. In vitro and clinical studies indicate that ivacaftor is primarily metabolized by CYP3A. M1 and M6 are the two major metabolites of ivacaftor in humans. M1 has approximately one-sixth the potency of ivacaftor and is considered pharmacologically active. M6 has less than one-fiftieth the potency of ivacaftor and is not considered pharmacologically active.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.4"></a><p></p><p class="First"><span class="Italics">Elimination</span></p><p>Following oral administration, the majority of ivacaftor (87.8%) is eliminated in the feces after metabolic conversion. The major metabolites M1 and M6 accounted for approximately 65% of the total dose eliminated with 22% as M1 and 43% as M6. There was negligible urinary excretion of ivacaftor as unchanged parent. The apparent terminal half-life was approximately 12 hours following a single dose. The mean apparent clearance (CL/F) of ivacaftor was similar for healthy subjects and patients with CF. The CL/F (SD) for the 150 mg dose was 17.3 (8.4) L/hr in healthy subjects.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.5"></a><p></p><p class="First"><span class="Bold Underline">Special populations</span></p><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.5.1"></a><p></p><p class="First"><span class="Italics">Hepatic impairment</span></p><p>Patients with moderately impaired hepatic function (Child-Pugh Class B, score 7 to 9) had similar ivacaftor C<span class="Sub">max</span>, but an approximately two-fold increase in ivacaftor AUC<span class="Sub">0-&infin;</span> compared with healthy subjects matched for demographics. Based on simulations of these results, a reduced KALYDECO dose of 150 mg once daily is recommended for patients with moderate hepatic impairment. The impact of mild hepatic impairment (Child-Pugh Class A) on pharmacokinetics of ivacaftor has not been studied, but the increase in ivacaftor AUC<span class="Sub">0-&infin;</span> is expected to be less than two-fold. Therefore, no dose adjustment is necessary for patients with mild hepatic impairment. The impact of severe hepatic impairment (Child-Pugh Class C, score 10-15) on pharmacokinetics of ivacaftor has not been studied. The magnitude of increase in exposure in these patients is unknown but is expected to be substantially higher than that observed in patients with moderate hepatic impairment. When benefits are expected to outweigh the risks, KALYDECO should be used with caution in patients with severe hepatic impairment at a dose of 150 mg given once daily or less frequently.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.5.2"></a><p></p><p class="First"><span class="Italics">Renal impairment</span></p><p>KALYDECO has not been studied in patients with mild, moderate or severe renal impairment (creatinine clearance less than or equal to 30 mL/min) or in patients with end-stage renal disease. No dose adjustments are recommended for mild and moderate renal impairment patients because of minimal elimination of ivacaftor and its metabolites in urine (only 6.6% of total radioactivity was recovered in the urine in a human PK study); however, caution is recommended when administering KALYDECO to patients with severe renal impairment or end-stage renal disease.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.5.3"></a><p></p><p class="First"><span class="Italics">Gender</span></p><p>The effect of gender on KALYDECO pharmacokinetics was evaluated using population pharmacokinetics of data from clinical studies of KALYDECO. No dose adjustments are necessary based on gender.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.5.4"></a><p></p><p class="First"><span class="Italics">Drug Interactions</span></p><p>Drug interaction studies were performed with KALYDECO and other drugs likely to be co-administered or drugs commonly used as probes for pharmacokinetic interaction studies [<span class="Italics">see <a href="#S7">Drug Interactions (7)</a></span>].</p><p>Dosing recommendations based on clinical studies or potential drug interactions with KALYDECO are presented below.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.5.5"></a><p></p><p class="First"><span class="Italics">Potential for Ivacaftor to Affect Other Drugs</span></p><p>Based on in vitro results, ivacaftor and metabolite M1 have the potential to inhibit CYP3A and P-gp. Clinical studies showed that KALYDECO is a weak inhibitor of CYP3A and P-gp, but not an inhibitor of CYP2C8. In vitro studies suggest that ivacaftor and M1 may inhibit CYP2C9. In vitro, ivacaftor, M1, and M6 were not inducers of CYP isozymes. Dosing recommendations for co-administered drugs with KALYDECO are shown in Figure 1.</p><p><span class="Bold">Figure 1: Impact of KALYDECO on Other Drugs </span></p><p><img src="image.cfm?id=129832&type=img&name=kalydeco%2D02.jpg" alt="Figure 1"></p><p><span class="Italics">Note:</span> The data obtained with substrates but without co-administration of KALYDECO are used as reference.<br>*NE: Norethindrone; **EE: Ethinyl Estradiol<br>The vertical lines are at 0.8, 1.0 and 1.25, respectively.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.5.6"></a><p></p><p class="First"><span class="Italics">Potential for Other Drugs to Affect Ivacaftor</span></p><p>In vitro studies showed that ivacaftor and metabolite M1 were substrates of CYP3A enzymes (i.e., CYP3A4 and CYP3A5). Exposure to ivacaftor is reduced by concomitant CYP3A inducers and increased by concomitant CYP3A inhibitors [<span class="Italics">see <a href="#S2.3">Dosage and Administration (2.3)</a></span> and<span class="Italics"><a href="#S7"> Drug Interactions (7)</a></span>]. KALYDECO dosing recommendations for co-administration with CYP3A inhibitors or inducers are shown in Figure 2.</p><p><span class="Bold">Figure 2: Impact of Other Drugs on KALYDECO</span></p><p><img src="image.cfm?id=129832&type=img&name=kalydeco%2D03.jpg" alt="Figure 2"></p><p><span class="Italics">Note:</span> The data obtained for KALYDECO without co-administration of inducers or inhibitors are used as reference.<br>The vertical lines are at 0.8, 1.0 and 1.25, respectively.</p></div></div></div></div><div class="Section"><a name="nlm43680-8"></a><a name="S13"></a><a name="section-12"></a><p></p><h1>13 NONCLINICAL TOXICOLOGY</h1><div class="Section"><a name="nlm34083-6"></a><a name="S13.1"></a><a name="section-12.1"></a><p></p><h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2><p class="First">Two-year studies were conducted in mice and rats to assess carcinogenic potential of KALYDECO. No evidence of tumorigenicity was observed in mice or rats at ivacaftor oral doses up to 200 mg/kg/day and 50 mg/kg/day, respectively (approximately equivalent to and 3 to 5 times the MRHD, respectively, based on summed AUCs of ivacaftor and its metabolites).</p><p>Ivacaftor was negative for genotoxicity in the following assays: Ames test for bacterial gene mutation, in vitro chromosomal aberration assay in Chinese hamster ovary cells, and in vivo mouse micronucleus test.</p><p>Ivacaftor impaired fertility and reproductive performance indices in male and female rats at 200 mg/kg/day (approximately 5 and 6 times, respectively, the MRHD based on summed AUCs of ivacaftor and its metabolites). Increases in prolonged diestrus were observed in females at 200 mg/kg/day. Ivacaftor also increased the number of females with all nonviable embryos and decreased corpora lutea, implantations, and viable embryos in rats at 200 mg/kg/day (approximately 6 times the MRHD based on summed AUCs of ivacaftor and its metabolites) when dams were dosed prior to and during early pregnancy. These impairments of fertility and reproductive performance in male and female rats at 200 mg/kg/day were attributed to severe toxicity. No effects on male or female fertility and reproductive performance indices were observed at &le;100 mg/kg/day (approximately 3 times the MRHD based on summed AUCs of ivacaftor and its metabolites).</p></div><div class="Section"><a name="nlm34091-9"></a><a name="S13.2"></a><a name="section-12.2"></a><p></p><h2>13.2	Animal Toxicology and/or Pharmacology</h2><p class="First">Cataracts were seen in juvenile rats dosed with ivacaftor from postnatal day 7-35 at dose levels of 10 mg/kg/day and higher (approximately 0.12 times the MRHD based on summed AUCs of ivacaftor and its metabolites). This finding has not been observed in older animals.</p></div></div><div class="Section"><a name="nlm34092-7"></a><a name="S14"></a><a name="section-13"></a><p></p><h1>14 CLINICAL STUDIES</h1><div class="Section"><a name="nlm42229-5"></a><a name="S14.1"></a><a name="section-13.1"></a><p></p><h2>14.1	Trials in Patients with CF who have a <span class="Italics">G551D</span> Mutation in the <span class="Italics">CFTR</span> Gene</h2><div class="Section"><a name="nlm42229-5"></a><a name="section-13.1.1"></a><p></p><p class="First"><span class="Italics">Dose Ranging:</span></p><p>Dose ranging for the clinical program consisted primarily of one double-blind, placebo-controlled, crossover trial in 39 adult (mean age 31 years) Caucasian patients with CF who had FEV<span class="Sub">1</span> &ge;40% predicted. Twenty patients with median predicted FEV<span class="Sub">1</span> at baseline of 56% (range: 42% to 109%) received KALYDECO 25, 75, 150 mg or placebo every 12 hours for 14 days and 19 patients with median predicted FEV<span class="Sub">1</span> at baseline of 69% (range: 40% to 122%) received KALYDECO 150, 250 mg or placebo every 12 hours for 28 days. The selection of the 150 mg every 12 hours dose was primarily based on nominal improvements in lung function (pre-dose FEV<span class="Sub">1</span>) and changes in pharmacodynamic parameters (sweat chloride and nasal potential difference). The twice-daily dosing regimen was primarily based on an apparent terminal plasma half-life of approximately 12 hours. Selection of the 150 mg dose of KALYDECO for children 6 to 11 years of age was based on achievement of comparable pharmacokinetics as those observed for adult patients.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-13.1.2"></a><p></p><p class="First"><span class="Italics">Efficacy:</span></p><p>The efficacy of KALYDECO in patients with CF who have a <span class="Italics">G551D</span> mutation in the <span class="Italics">CFTR</span> gene was evaluated in two randomized, double-blind, placebo-controlled clinical trials in 213 clinically stable patients with CF (109 receiving KALYDECO 150 mg twice daily). All eligible patients from these trials were rolled over into an open-label extension study.</p><p>Trial 1 evaluated 161 patients with CF who were 12 years of age or older (mean age 26 years) with FEV<span class="Sub">1</span> at screening between 40-90% predicted [mean FEV<span class="Sub">1</span> 64% predicted at baseline (range: 32% to 98%)]. Trial 2 evaluated 52 patients who were 6 to 11 years of age (mean age 9 years) with FEV<span class="Sub">1</span> at screening between 40-105% predicted [mean FEV<span class="Sub">1</span> 84% predicted at baseline (range: 44% to 134%)]. Patients who had persistent <span class="Italics">Burkholderia cenocepacia, Burkholderia dolosa</span>, or <span class="Italics">Mycobacterium abscessus</span> isolated from sputum at screening and those with abnormal liver function defined as 3 or more liver function tests (ALT, AST, AP, GGT, total bilirubin) &ge;3 times the upper limit of normal were excluded.</p><p>Patients in both trials were randomized 1:1 to receive either 150 mg of KALYDECO or placebo every 12 hours with food containing fat for 48 weeks in addition to their prescribed CF therapies (e.g., tobramycin, dornase alfa). The use of inhaled hypertonic saline was not permitted.</p><p>The primary efficacy endpoint in both studies was improvement in lung function as determined by the mean absolute change from baseline in percent predicted pre-dose FEV<span class="Sub">1</span> through 24 weeks of treatment.</p><p>In both studies, treatment with KALYDECO resulted in a significant improvement in FEV<span class="Sub">1</span>. The treatment difference between KALYDECO and placebo for the mean absolute change in percent predicted FEV<span class="Sub">1</span> from baseline through Week 24 was 10.6 percentage points (<span class="Italics">P</span> &lt; 0.0001) in Trial 1 and 12.5 percentage points (<span class="Italics">P</span> &lt; 0.0001) in Trial 2 (Figure 3). These changes persisted through 48 weeks. Improvements in percent predicted FEV<span class="Sub">1</span> were observed regardless of age, disease severity, sex, and geographic region.</p><p><span class="Bold">Figure 3: Mean Absolute Change from Baseline in Percent Predicted FEV<span class="Sub">1</span> *</span></p><p><img src="image.cfm?id=129832&type=img&name=kalydeco%2D04.jpg" alt="Figure 3"></p><p>*Primary endpoint was assessed at the 24-week time point.</p><p>Other efficacy variables included absolute change in sweat chloride from baseline to Week 24 [<span class="Italics">see <a href="#S12.2">Clinical Pharmacology (12.2)</a></span>], time to first pulmonary exacerbation through Week 48 (Trial 1 only), absolute change in weight from baseline to Week 48, and improvement in cystic fibrosis symptoms including relevant respiratory symptoms such as cough, sputum production, and difficulty breathing. For the purpose of the study, a pulmonary exacerbation was defined as a change in antibiotic therapy (IV, inhaled, or oral) as a result of 4 or more of 12 pre-specified sino-pulmonary signs/symptoms. Patients treated with KALYDECO demonstrated statistically significant improvements in risk of pulmonary exacerbations, CF symptoms (in Trial 1 only), and gain in body weight (Table 2). Weight data, when expressed as body mass index normalized for age and sex in patients &lt;20 years of age, was consistent with absolute change from baseline in weight.</p><a name="table2"></a><table width="100%"><caption><span>Table 2:  Effect of KALYDECO on Other Efficacy Endpoints in Trials 1 and 2</span></caption><col align="left" valign="bottom" width="30%"><col align="center" valign="bottom" width="27%"><col align="center" valign="bottom" width="8%"><col align="center" valign="bottom" width="27%"><col align="center" valign="bottom" width="8%"><thead><tr class="First"><th align="left"></th><th class="Botrule" align="center" colspan="2">Trial 1</th><th class="Botrule" align="center" colspan="2">Trial 2</th></tr><tr class="Last"><th align="left">Endpoint</th><th align="center">Treatment difference<a class="Sup" href="#footnote-1" name="footnote-reference-1">*</a><br>(95% CI)</th><th align="center"><span class="Italics">P </span>value</th><th align="center">Treatment difference<a class="Sup" href="#footnote-1">*</a><br>(95% CI)</th><th align="center"><span class="Italics">P </span>value</th></tr></thead><tfoot><tr class="First Last"><td align="left" colspan="5" valign="top">CI:  confidence interval; NA: not analyzed due to low incidence of events</td></tr><tr><td align="left" colspan="5"><dl class="Footnote"><dt><a href="#footnote-reference-1" name="footnote-1">*</a></dt><dd>Treatment difference = effect of KALYDECO &minus; effect of Placebo</dd><dt><a href="#footnote-reference-2" name="footnote-2">&dagger;</a></dt><dd>Hazard ratio for time to first pulmonary exacerbation</dd></dl></td></tr></tfoot><tbody><tr class="First"><td align="left" colspan="5"><span class="Bold">Mean absolute change from baseline in CF symptom score (points)</span></td></tr><tr valign="top"><td align="left">Through Week 24</td><td align="center">8.1<br>(4.7, 11.4)</td><td align="center">&lt;0.0001</td><td align="center">6.1<br>(-1.4, 13.5)</td><td align="center">0.1092</td></tr><tr class="Botrule" valign="top"><td align="left">Through Week 48</td><td align="center">8.6<br>(5.3, 11.9)</td><td align="center">&lt;0.0001</td><td align="center">5.1<br>(-1.6, 11.8)</td><td align="center">0.1354</td></tr><tr><td align="left" colspan="5"><span class="Bold">Relative risk of pulmonary exacerbation</span></td></tr><tr><td align="left">Through Week 24</td><td align="center">0.40<a class="Sup" href="#footnote-2" name="footnote-reference-2">&dagger;</a></td><td align="center">0.0016</td><td align="center">NA</td><td align="center">NA</td></tr><tr class="Botrule"><td align="left">Through Week 48</td><td align="center">0.46<a class="Sup" href="#footnote-2">&dagger;</a></td><td align="center">0.0012</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left" colspan="5"><span class="Bold">Mean absolute change from baseline in body weight (kg)</span></td></tr><tr valign="top"><td align="left">At Week 24</td><td align="center">2.8<br>(1.8, 3.7)</td><td align="center">&lt;0.0001</td><td align="center">1.9<br>(0.9, 2.9)</td><td align="center">0.0004</td></tr><tr class="Botrule Last" valign="top"><td align="left">At Week 48</td><td align="center">2.7<br>(1.3, 4.1)</td><td align="center">0.0001</td><td align="center">2.8<br>(1.3, 4.2)</td><td align="center">0.0002</td></tr></tbody></table></div></div><div class="Section"><a name="nlm42229-5"></a><a name="S14.2"></a><a name="section-13.2"></a><p></p><h2>14.2         Trial in Patients with a <span class="Italics">G1244E, G1349D, G178R, G551S, G970R, S1251N, S1255P, S549N,</span> or<span class="Italics"> S549R</span> Mutation in the <span class="Italics">CFTR</span> Gene</h2><p class="First">The efficacy and safety of KALYDECO in patients with CF who have a <span class="Italics">G1244E, G1349D, G178R, G551S, G970R, S1251N, S1255P, S549N, </span>or<span class="Italics"> S549R</span> mutation in the <span class="Italics">CFTR</span> gene were evaluated in a two-part, randomized, double-blind, placebo-controlled, crossover design  clinical trial in 39 patients with CF (Trial 4). Patients who completed Part 1 of this trial continued into the 16-week open-label Part 2 of the study. The mutations studied were <span class="Italics">G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P,</span> and <span class="Italics">G1349D. </span>See<span class="Italics"><a href="#S14.1"> Clinical Studies (14.1) </a></span>for efficacy in patients with a <span class="Italics">G551D</span> mutation.</p><p>Patients were 6 years of age or older (mean age 23 years) with FEV<span class="Sub">1</span> &ge;40% at screening [mean FEV<span class="Sub">1</span> at baseline 78% predicted (range: 43% to 119%)]. Patients with evidence of  colonization with <span class="Italics">Burkholderia cenocepacia, Burkholderia dolosa</span>, or <span class="Italics">Mycobacterium abscessus</span> and those with abnormal liver function defined as 3 or more liver function tests (ALT, AST, AP, GGT, total bilirubin) &ge;3 times the upper limit of normal at screening were excluded.</p><p>Patients were randomized 1:1 to receive either 150 mg of KALYDECO or placebo every 12 hours with food containing fat for 8 weeks in addition to their prescribed CF therapies during the first treatment period and crossed over to the other treatment for the second 8 weeks. The two 8-week treatment periods were separated by a 4- to 8-week washout period. The use of inhaled hypertonic saline was not permitted.</p><p>The primary efficacy endpoint was improvement in lung function as determined by the mean absolute change from baseline in percent predicted FEV<span class="Sub">1</span> through 8 weeks of treatment. Other efficacy variables included absolute change from baseline in sweat chloride through 8 weeks of treatment [<span class="Italics">see <a href="#S12.2">Clinical Pharmacology (12.2)</a></span>], absolute change from baseline in body mass index (BMI) at 8 weeks of treatment (including body weight at 8 weeks), and improvement in cystic fibrosis symptoms (including relevant respiratory symptoms such as cough, sputum production, and difficulty breathing) through 8 weeks of treatment. For the overall population of the 9 mutations studied, treatment with KALYDECO compared to placebo resulted in significant improvement in percent predicted FEV<span class="Sub">1 </span>[10.7 through Week 8 (<span class="Italics">P</span> &lt; 0.0001)], BMI [0.66 kg/m<span class="Sup">2 </span>at Week 8 (<span class="Italics">P </span>&lt; 0.0001)], and cystic fibrosis respiratory symptom score [9.6 through Week 8 (<span class="Italics">P</span> = 0.0004)]; however, there was a high degree of variability of efficacy responses among the 9 mutations (Table 3). Based on clinical and pharmacodynamic (sweat chloride) responses to ivacaftor, efficacy in patients with the <span class="Italics">G970R</span> mutation could not be established [<span class="Italics">see <a href="#S12.2">Clinical Pharmacology (12.2)</a></span>]<span class="Italics">.</span></p><a name="table3"></a><table width="100%"><caption><span>Table 3: Effect of KALYDECO for Efficacy Variables in the Overall Populations and for Specific CFTR Mutations</span></caption><col align="left" valign="top" width="14%"><col align="center" valign="top" width="15%"><col align="center" valign="top" width="15%"><col align="center" valign="top" width="15%"><col align="center" valign="top" width="14%"><col align="center" valign="top" width="27%"><thead><tr class="First"><th class="Lrule Rrule" align="left">Mutation (n)</th><th class="Botrule Rrule" align="center" colspan="3">Absolute change in percent predicted FEV<span class="Sub">1</span></th><th class="Botrule Rrule" align="center">BMI<br>(kg/m<span class="Sup">2</span>)</th><th class="Botrule Rrule" align="center">CF Respiratory Symptom Score<br>(points)</th></tr><tr class="Last"><th class="Lrule Rrule" align="left"></th><th align="center">At Week 2</th><th align="center">At Week 4</th><th class="Rrule" align="center">At Week 8</th><th class="Rrule" align="center">At Week 8</th><th class="Rrule" align="center">At Week 8</th></tr></thead><tfoot><tr><td align="left" colspan="6"><dl class="Footnote"><dt><a href="#footnote-reference-3" name="footnote-3">*</a></dt><dd>Result for weight gain as a component of body mass index was consistent with BMI.</dd><dt><a href="#footnote-reference-4" name="footnote-4">&dagger;</a></dt><dd>Statistical testing was not performed due to small numbers for individual mutations.</dd><dt><a href="#footnote-reference-5" name="footnote-5">&Dagger;</a></dt><dd>Reflects results from the one patient with the <span class="Italics">G551S</span> mutation with data at the 8-week time point.</dd></dl></td></tr></tfoot><tbody><tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="6">All patients (n=39)<br>Results shown as mean (95% CI) change from baseline KALYDECO vs placebo-treated patients:</td></tr><tr class="Botrule"><td class="Lrule Rrule" align="left"></td><td align="center">8.3 (4.5, 12.1)</td><td align="center">10.0 (6.2, 13.8)</td><td class="Rrule" align="center">13.8 (9.9, 17.6)</td><td class="Rrule" align="center">0.66<a class="Sup" href="#footnote-3" name="footnote-reference-3">*</a> (0.34, 0.99)</td><td class="Rrule" align="center">12.8 (6.7, 18.9)</td></tr><tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="6"><span class="Bold">Patients grouped under mutation types (n)</span><br>Results shown as mean (minimum, maximum) for change from baseline for KALYDECO-treated patients<a class="Sup" href="#footnote-4" name="footnote-reference-4">&dagger;</a>:</td></tr><tr><td class="Lrule Rrule" align="left"><span class="Italics">G1244E</span> (5)</td><td align="center">11 (-5, 25)</td><td align="center">6 (-5, 13)</td><td class="Rrule" align="center">8 (-1, 18)</td><td class="Rrule" align="center">0.63 (0.34, 1.32)</td><td class="Rrule" align="center">3.3 (-27.8, 22.2)</td></tr><tr><td class="Lrule Rrule" align="left"><span class="Italics">G1349D</span> (2)</td><td align="center">19 (5, 33)</td><td align="center">18 (2, 35)</td><td class="Rrule" align="center">20 (3, 36)</td><td class="Rrule" align="center">1.15 (1.07, 1.22)</td><td class="Rrule" align="center">16.7 (-11.1, 44.4)</td></tr><tr><td class="Lrule Rrule" align="left"><span class="Italics">G178R</span> (5)</td><td align="center">7 (1, 17)</td><td align="center">10 (-2, 21)</td><td class="Rrule" align="center">8 (-1, 18)</td><td class="Rrule" align="center">0.85 (0.33, 1.46)</td><td class="Rrule" align="center">20.0 (5.6, 50.0)</td></tr><tr><td class="Lrule Rrule" align="left"><span class="Italics">G551S</span> (2)</td><td align="center">0 (-5, 5)</td><td align="center">0.3 (-5, 6)</td><td class="Rrule" align="center">3<a class="Sup" href="#footnote-5" name="footnote-reference-5">&Dagger;</a></td><td class="Rrule" align="center">0.16<a class="Sup" href="#footnote-5">&Dagger;</a></td><td class="Rrule" align="center">16.7<a class="Sup" href="#footnote-5">&Dagger;</a></td></tr><tr><td class="Lrule Rrule" align="left"><span class="Italics">G970R</span> (4)</td><td align="center">7 (1, 13)</td><td align="center">7 (1, 14)</td><td class="Rrule" align="center">3 (-1, 5)</td><td class="Rrule" align="center">0.48 (-0.38, 1.75)</td><td class="Rrule" align="center">1.4 (-16.7, 16.7)</td></tr><tr><td class="Lrule Rrule" align="left"><span class="Italics">S1251N </span>(8)</td><td align="center">2 (-23, 20)</td><td align="center">8 (-13, 26)</td><td class="Rrule" align="center">9 (-20, 21)</td><td class="Rrule" align="center">0.73 (0.08, 1.83)</td><td class="Rrule" align="center">23.3 (5.6, 50.0)</td></tr><tr><td class="Lrule Rrule" align="left"><span class="Italics">S1255P</span> (2)</td><td align="center">11 (8, 14)</td><td align="center">9 (5, 13)</td><td class="Rrule" align="center">3 (-1, 8)</td><td class="Rrule" align="center">1.62 (1.39, 1.84)</td><td class="Rrule" align="center">8.3 (5.6, 11.1)</td></tr><tr><td class="Lrule Rrule" align="left"><span class="Italics">S549N</span> (6)</td><td align="center">11 (5, 16)</td><td align="center">8 (-9, 19)</td><td class="Rrule" align="center">11 (-2, 20)</td><td class="Rrule" align="center">0.79 (0.00, 1.91)</td><td class="Rrule" align="center">8.8 (-8.3, 27.8)</td></tr><tr class="Last"><td class="Lrule Rrule" align="left"><span class="Italics">S549R</span> (4)</td><td align="center">3 (-4, 8)</td><td align="center">4 (-4, 10)</td><td class="Rrule" align="center">5 (-3, 13)</td><td class="Rrule" align="center">0.53 (0.33, 0.80)</td><td class="Rrule" align="center">6.9 (0.0, 11.1)</td></tr></tbody></table></div><div class="Section"><a name="nlm42229-5"></a><a name="S14.3"></a><a name="section-13.3"></a><p></p><h2>14.3	Trial in Patients Homozygous for the <span class="Italics">F508del</span> Mutation in the <span class="Italics">CFTR</span> Gene</h2><p class="First">Trial 3 was a 16-week randomized, double-blind, placebo-controlled, parallel-group trial in 140 patients with CF age 12 years and older who were homozygous for the <span class="Italics">F508del</span> mutation in the <span class="Italics">CFTR</span> gene and who had FEV<span class="Sub">1</span> &ge;40% predicted. Patients were randomized 4:1 to receive KALYDECO 150 mg (n=112) every twelve hours or placebo (n=28) in addition to their prescribed CF therapies. The mean age of patients enrolled was 23 years and the mean baseline FEV<span class="Sub">1</span> was 79% predicted (range 40% to 129%). As in Trials 1 and 2, patients who had persistent <span class="Italics">Burkholderia cenocepacia, Burkholderia dolosa</span>, or <span class="Italics">Mycobacterium abscessus</span> isolated from sputum at screening and those with abnormal liver function defined as 3 or more liver function tests (ALT, AST, AP, GGT, total bilirubin) &ge;3 times the upper limit of normal were excluded. The use of inhaled hypertonic saline was not permitted.</p><p>The primary endpoint was improvement in lung function as determined by the mean absolute change from baseline through Week 16 in percent predicted FEV<span class="Sub">1</span>. Treatment with KALYDECO resulted in no improvement in FEV<span class="Sub">1</span> relative to placebo in patients with CF homozygous for the <span class="Italics">F508del</span> mutation in the <span class="Italics">CFTR</span> gene [mean absolute change from baseline through Week 16 in percent predicted FEV<span class="Sub">1</span> was 1.5% and -0.2% for patients in the KALYDECO and placebo-treated groups, respectively (<span class="Italics">P</span> = 0.15)]. There were no meaningful differences between patients treated with KALYDECO compared to placebo for secondary endpoints (change in CF symptoms, change in weight, or change in sweat chloride concentration).</p></div></div><div class="Section"><a name="nlm34069-5"></a><a name="S16"></a><a name="section-14"></a><p></p><h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1><p class="First">KALYDECO<span class="Sup">&reg;</span> (ivacaftor) is supplied as light blue, film-coated, capsule-shaped tablets containing 150 mg of ivacaftor. Each tablet is printed with the characters "V 150" on one side and plain on the other, and is packaged as follows:</p><table class="Noautorules" width="100%"><col align="left" valign="top" width="3%"><col align="left" valign="top" width="72%"><col align="left" valign="top" width="25%"><tbody class="Headless"><tr><td align="left"></td><td align="left">56-count carton (contains 4 individual blister cards of 14 tablets per card)</td><td align="left"><span class="Bold">NDC</span> 51167-200-01</td></tr><tr><td align="left"></td><td align="left">60-count bottle</td><td align="left"><span class="Bold">NDC</span> 51167-200-02</td></tr></tbody></table><div class="Section"><a name="nlm44425-7"></a><a name="section-14.1"></a><p></p><p class="First">Store at 20-25&ordm;C (68-77&ordm;F); excursions permitted to 15-30&ordm;C (59-86&ordm;F) [see USP Controlled Room Temperature].</p></div></div><div class="Section"><a name="nlm34076-0"></a><a name="S17"></a><a name="section-15"></a><p></p><h1>17 PATIENT COUNSELING INFORMATION</h1><p class="First">Advise the patient to read the FDA-approved patient labeling (<a href="#pi">Patient Information</a>).</p><div class="Section"><a name="nlm42229-5"></a><a name="S17.1"></a><a name="section-15.1"></a><p></p><h2>17.1 	Transaminase (ALT or AST) Elevations and Monitoring</h2><p class="First">Inform patients that elevation in liver tests have occurred in patients treated with KALYDECO. Liver function tests will be performed prior to initiating KALYDECO, every 3 months during the first year of treatment and annually thereafter [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S17.2"></a><a name="section-15.2"></a><p></p><h2>17.2 	Drug Interactions with CYP3A Inducers and Inhibitors</h2><p class="First">Ask patients to tell you all the medications they are taking including any herbal supplements or vitamins. Co-administration of KALYDECO with strong CYP3A inducers (e.g., rifampin, St. John's Wort) is not recommended as they may reduce the therapeutic effectiveness of KALYDECO. Reduction of the dose of KALYDECO to 150 mg twice a week is recommended when co-administered with strong CYP3A inhibitors, such as ketoconazole. Dose reduction to 150 mg once daily is recommended when co-administered with moderate CYP3A inhibitors, such as fluconazole. Food containing grapefruit or Seville oranges should be avoided [<span class="Italics">see <a href="#S7.1">Drug Interactions (7.1</a>, <a href="#S7.2">7.2)</a></span> and<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>].</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S17.3"></a><a name="section-15.3"></a><p></p><h2>17.3 	Use in Patients with Hepatic Impairment</h2><p class="First">Inquire and/or assess whether patients have liver impairment. Reduce the dose of KALYDECO in patients with moderately impaired hepatic function (Child-Pugh Class B, score 7 to 9) to 150 mg once daily. KALYDECO has not been studied in patients with severe hepatic impairment (Child-Pugh Class C, score 10-15); however, exposure is expected to be substantially higher than that observed in patients with moderate hepatic impairment. When benefits are expected to outweigh the risks, KALYDECO should be used with caution in patients with severe hepatic impairment at a dose of 150 mg given once daily or less frequently. No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh Class A, score 5-6) [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S17.4"></a><a name="section-15.4"></a><p></p><h2>17.4 	Take with Fat-Containing Food</h2><p class="First">Inform your patients that KALYDECO is best absorbed by the body when taken with food that contains fat. A typical CF diet will satisfy this requirement. Examples include eggs, butter, peanut butter, cheese pizza, etc.</p></div></div><div class="Section"><a name="nlm42229-5"></a><a name="section-16"></a><p></p><p class="First">Manufactured for<br>Vertex Pharmaceuticals Incorporated<br>Boston, MA 02210</p><p>KALYDECO, VERTEX, and the VERTEX triangle logo are registered trademarks of Vertex Pharmaceuticals Incorporated.<br>All other trademarks referenced herein are the property of their respective owners.<br>&copy;2014 Vertex Pharmaceuticals Incorporated<br>ALL RIGHTS RESERVED<br>69264-04<br>Revised June 2014</p></div><div class="Section"><a name="nlm42230-3"></a><a name="pi"></a><a name="section-17"></a><p></p><h1>PATIENT INFORMATION</h1><p class="First"><span class="Bold">KALYDECO (kuh-LYE-deh-koh)<br>(ivacaftor)<br>Film-Coated Tablets</span></p><p>Read this Patient Information before you start taking KALYDECO and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.</p><p><span class="Bold">What is KALYDECO? </span></p><p>KALYDECO is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in their CF gene: <span class="Italics">G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, </span>or <span class="Italics">S549R</span>.</p><p>KALYDECO is not for use in people with CF due to other mutations in the CF gene. KALYDECO is not effective in CF patients with two copies of the <span class="Italics">F508del</span> mutation (<span class="Italics">F508del/F508del</span>) in the CF gene.</p><p>It is not known if KALYDECO is safe and effective in children under 6 years of age.</p><p><span class="Bold">Who should not take KALYDECO?</span></p><p><span class="Bold">Do not take KALYDECO if you take certain medicines or herbal supplements such as: </span></p><ul class="Disc"><li>the antibiotics rifampin (Rifamate<span class="Sup">&reg;</span>, Rifater<span class="Sup">&reg;</span>) or rifabutin (Mycobutin<span class="Sup">&reg;</span>)</li><li>seizure medications such as   phenobarbital, carbamazepine (Tegretol<span class="Sup">&reg;</span>, Carbatrol<span class="Sup">&reg;</span>,   Equetro<span class="Sup">&reg;</span>) or phenytoin (Dilantin<span class="Sup">&reg;</span>, Phenytek<span class="Sup">&reg;</span>)</li><li>St. John's Wort</li></ul><p>Talk to your doctor before taking KALYDECO if you take any of the medicines or supplements listed above.</p><p><span class="Bold">What should I tell my doctor before taking KALYDECO? </span></p><p>Before you take KALYDECO, tell your doctor if you:</p><ul class="Disc"><li>have liver or kidney problems</li><li>drink grapefruit juice, or eat grapefruit or Seville oranges</li><li>are pregnant or plan to become   pregnant. It is not known if KALYDECO will harm your unborn baby. You and   your doctor should decide if you will take KALYDECO while you are   pregnant.</li><li>are breastfeeding or planning to   breastfeed. It is not known if KALYDECO passes into your breast milk. You   and your doctor should decide if you will take KALYDECO while you are   breastfeeding.</li></ul><p>KALYDECO may affect the way other medicines work, and other medicines may affect how KALYDECO works.</p><p><span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins, and herbal supplements, as the dose of KALYDECO may need to be adjusted when taken with certain medications.</p><p>Ask your doctor or pharmacist for a list of these medicines if you are not sure.</p><p>Especially tell your doctor if you take:</p><ul class="Disc"><li>antifungal medications such as   ketoconazole (e.g., Nizoral<span class="Sup">&reg;</span>), itraconazole (e.g., Sporanox<span class="Sup">&reg;</span>),   posaconazole (e.g., Noxafil<span class="Sup">&reg;</span>), voriconazole (e.g., Vfend<span class="Sup">&reg;</span>),   or fluconazole (e.g., Diflucan<span class="Sup">&reg;</span>)</li><li>antibiotics such as telithromycin   (e.g., Ketek<span class="Sup">&reg;</span>), clarithromycin (e.g., Biaxin<span class="Sup">&reg;</span>), or   erythromycin (e.g., Ery-Tab<span class="Sup">&reg;</span>)</li></ul><p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p><p><span class="Bold">How should I take KALYDECO?</span></p><ul class="Disc"><li>Take KALYDECO exactly as your doctor tells you to take it.</li><li>Always take KALYDECO with food that contains fat. Examples of fat-containing foods include eggs, butter, peanut butter, cheese pizza, etc.</li><li>Your doses of KALYDECO should be taken 12 hours apart.</li><li>Each KALYDECO box contains 4 individual blister cards.</li><li>Each blister card contains 14 pills&mdash;7 morning doses and 7 evening doses.</li><li>In the morning, unpeel the paper backing from a blister card to remove 1 KALYDECO pill and take it with food that contains fat.</li><li>In the evening, 12 hours later, open another blister card to remove 1 KALYDECO pill and take it with food that contains fat.</li><li>You may cut along the dotted line to separate your doses from the blister card.</li></ul><p><span class="Bold">What should I avoid while taking KALYDECO?</span></p><ul class="Disc"><li>KALYDECO can cause dizziness in some   people who take it. Do not drive a car, use machinery or do anything that   needs you to be alert until you know how KALYDECO affects you.</li><li>You should avoid food containing   grapefruit or Seville oranges while you are taking KALYDECO.</li></ul><p><span class="Bold">What are the possible side effects of KALYDECO?</span></p><p><span class="Bold">KALYDECO can cause serious side effects.</span></p><p><span class="Bold">High liver enzymes in the blood have been reported in patients receiving KALYDECO. </span>Your doctor will do blood tests to check your liver:</p><ul class="Disc"><li> before you start KALYDECO</li><li> every 3 months during your first year of taking KALYDECO</li><li> every year while you are taking KALYDECO</li></ul><p>Call your doctor right away if you have any of the following symptoms of liver problems:</p><ul class="Disc"><li>   pain or discomfort in the upper right stomach (abdominal) area</li><li>   yellowing of your skin or the white part of your eyes</li><li>   loss of appetite</li><li>   nausea or vomiting</li><li>   dark, amber-colored urine</li></ul><p>The most common side effects of KALYDECO include:</p><ul class="Disc"><li>headache</li><li>upper respiratory tract infection   (common cold), including:<ul class="Disc"><li>sore throat</li><li>nasal or sinus congestion</li><li>runny nose</li></ul></li><li>stomach (abdominal) pain</li><li>diarrhea</li><li>rash</li><li>nausea</li><li>dizziness</li></ul><p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p><p>These are not all the possible side effects of KALYDECO. For more information, ask your doctor or pharmacist.</p><p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p><p><span class="Bold">How should I store KALYDECO?</span></p><ul class="Disc"><li>Store KALYDECO   at room temperature between 68&ordm;F to 77&ordm;F (20&ordm;C to 25&ordm;C).</li><li>Do not use KALYDECO after the   expiration date on the package.</li></ul><p><span class="Bold">Keep KALYDECO and all medicines out of the reach of children.</span></p><p><span class="Bold">General information about KALYDECO</span></p><p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use KALYDECO for a condition for which it was not prescribed. Do not give KALYDECO to other people, even if they have the same symptoms you have. It may harm them.</p><p>This Patient Information summarizes the most important information about KALYDECO. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about KALYDECO that is written for health professionals.</p><p>For more information, go to www.kalydeco.com or call 1-877-752-5933.</p><p><span class="Bold">What are the ingredients in KALYDECO?</span></p><p>Active ingredient: ivacaftor</p><p>Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate.</p><p>The tablet film coat contains: carnauba wax, FD&amp;C Blue #2, PEG 3350, polyvinyl alcohol, talc, and titanium dioxide.</p><p>The printing ink contains: ammonium hydroxide, iron oxide black, propylene glycol, and shellac.</p><p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p><p>Manufactured for:<br>Vertex Pharmaceuticals Incorporated<br>50 Northern Avenue<br>Boston, MA 02210</p><p>Approved June 2014</p><p>KALYDECO, VERTEX, and the VERTEX triangle logo are registered trademarks of Vertex Pharmaceuticals Incorporated.<br>All other trademarks referenced herein are the property of their respective owners.<br>&copy;2014 Vertex Pharmaceuticals Incorporated<br>ALL RIGHTS RESERVED<br>69264-04</p></div><div class="Section"><a name="nlm51945-4"></a><a name="section-18"></a><p></p><p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 150 mg Carton</span></p><p>NDC 51167-200-02</p><p>Rx only</p><p><span class="Bold">kalydeco&trade;<br>(ivacaftor) tablets</span></p><p>150 mg</p><p>60 tablets</p><div class="Figure"><img src="image.cfm?id=129832&type=img&name=kalydeco%2D05.jpg" alt="PRINCIPAL DISPLAY PANEL - 150 mg Carton"></div></div><div class="Section"><a name="nlm51945-4"></a><a name="section-19"></a><p></p><h1>PRINCIPAL DISPLAY PANEL - 56 Tablet Blister Card Carton</h1><p class="First">NDC 51167-200-01</p><p>Rx only</p><p><span class="Bold">kalydeco</span><span class="Sup">&reg;</span><br><span class="Bold">(ivacaftor) tablets</span></p><p>150 mg per tablet</p><p>Carton contains<br>4 individual blister cards<br>of 14 tablets per card.</p><p>56 tablets</p><div class="Figure"><img src="image.cfm?id=129832&type=img&name=kalydeco%2D06.jpg" alt="PRINCIPAL DISPLAY PANEL - 56 Tablet Blister Card Carton"></div></div></div><div class="DataElementsTables"><table width="100%" cellPadding="3" cellSpacing="0" class="contentTablePetite"><tbody><tr><td class="contentTableTitle"><strong>KALYDECO&nbsp;							</strong><br><span class="contentTableReg">ivacaftor tablet, film coated</span></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%"><tr><td class="formHeadingTitle" colspan="4">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Product Type</td><td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td><td class="formLabel">Item Code (Source)</td><td class="formItem">NDC:51167-200</td></tr><tr class="formTableRow"><td class="formLabel" width="30%">Route of Administration</td><td class="formItem">ORAL</td><td class="formLabel" width="30%">DEA Schedule</td><td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;							</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td></tr><tr><th scope="col" class="formTitle">Ingredient Name</th><th scope="col" class="formTitle">Basis of Strength</th><th scope="col" class="formTitle">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ivacaftor</strong> (ivacaftor) </td><td class="formItem">ivacaftor</td><td class="formItem">150&nbsp;mg</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="2">Inactive Ingredients</td></tr><tr><th scope="col" class="formTitle">Ingredient Name</th><th scope="col" class="formTitle">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>SILICON DIOXIDE</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MM2/S)</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>MAGNESIUM STEARATE</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>CARNAUBA WAX</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>FD&amp;C Blue No. 2</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>TALC</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TITANIUM DIOXIDE</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>AMMONIA</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>PROPYLENE GLYCOL</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>SHELLAC</strong></td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="4">Product Characteristics</td></tr><tr class="formTableRowAlt"><td class="formLabel">Color</td><td class="formItem">BLUE</td><td class="formLabel">Score</td><td class="formItem">no score</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">OVAL</td><td class="formLabel">Size</td><td class="formItem">5mm</td></tr><tr class="formTableRowAlt"><td class="formLabel">Flavor</td><td class="formItem"></td><td class="formLabel">Imprint Code</td><td class="formItem">                                                      V;150                        </td></tr><tr class="formTableRow"><td class="formLabel">Contains</td><td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="5">Packaging</td></tr><tr><th class="formTitle" width="1" scope="col">#</th><th class="formTitle" scope="col">Item Code</th><th class="formTitle" scope="col">Package Description</th><th class="formTitle" scope="col">Marketing Start Date</th><th class="formTitle" scope="col">Marketing End Date</th></tr><tr class="formTableRowAlt"><th class="formItem" scope="row">1</th><td class="formItem">NDC:51167-200-01</td><td class="formItem">4  in 1 CARTON</td><td class="formItem"></td><td class="formItem"></td></tr><tr class="formTableRowAlt"><th class="formItem" scope="row">1</th><td class="formItem"></td><td class="formItem">14  in 1 BLISTER PACK</td><td class="formItem"></td><td class="formItem"></td></tr><tr class="formTableRow"><th class="formItem" scope="row">2</th><td class="formItem">NDC:51167-200-02</td><td class="formItem">1  in 1 CARTON</td><td class="formItem"></td><td class="formItem"></td></tr><tr class="formTableRow"><th class="formItem" scope="row">2</th><td class="formItem"></td><td class="formItem">60  in 1 BOTTLE</td><td class="formItem"></td><td class="formItem"></td></tr></table></td></tr><tr><td></td></tr><tr><td class="normalizer"><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td></tr><tr><th class="formTitle" scope="col">Marketing Category</th><th class="formTitle" scope="col">Application Number or Monograph Citation</th><th class="formTitle" scope="col">Marketing Start Date</th><th class="formTitle" scope="col">Marketing End Date</th></tr><tr class="formTableRowAlt"><td class="formItem">NDA</td><td class="formItem">NDA203188</td><td class="formItem">01/31/2012</td><td class="formItem"></td></tr></table></td></tr></tbody></table><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>Vertex Pharmaceuticals Incorporated							(602478257)						</td></tr></table><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td></tr><tr><th class="formTitle" scope="col">Name</th><th class="formTitle" scope="col">Address</th><th class="formTitle" scope="col">ID/FEI</th><th class="formTitle" scope="col">Business Operations</th></tr><tr class="formTableRowAlt"><td class="formItem">Vertex Pharmaceuticals Incorporated</td><td class="formItem"></td><td class="formItem">602478257</td><td class="formItem">MANUFACTURE(51167-200), ANALYSIS(51167-200)</td></tr></table><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td></tr><tr><th class="formTitle" scope="col">Name</th><th class="formTitle" scope="col">Address</th><th class="formTitle" scope="col">ID/FEI</th><th class="formTitle" scope="col">Business Operations</th></tr><tr class="formTableRowAlt"><td class="formItem">Almac Pharma Services Ltd.</td><td class="formItem"></td><td class="formItem">233170864</td><td class="formItem">PACK(51167-200), LABEL(51167-200)</td></tr></table></div><p><div class="EffectiveDate">Revised: 6/2014<div class="DocumentMetadata"><div><a href="javascript:toggleMixin();">Document Id: </a>0178bce3-e1ae-4a30-beb9-1d853a5e47d3</div><div>Set id: 0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25</div><div>Version: 9</div><div>Effective Time: 20140619</div></div></div>&nbsp;<div class="DistributorName">Vertex Pharmaceuticals Incorporated</div></p>			</div>			</div>			<div id="nlmfooter">	<a href="http://www.nlm.nih.gov">		<img  src="/dailymed/images/logo.gif"		alt="Visit The National Library of Medicine" />	</a>	<a href="http://www.nlm.nih.gov/copyright.html">Copyright</a>,	<a href="http://www.nlm.nih.gov/privacy.html">Privacy</a>,	<a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a><br />	<a href="http://www.nlm.nih.gov">U.S. National Library of Medicine</a>, 8600 Rockville Pike, Bethesda, MD 20894<br />	<a href="http://www.nih.gov/">National Institutes of Health</a>,	<a href="http://www.hhs.gov/">Health &amp; Human Services</a></div>		</body>	</html>